Neumora Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Legal Proceedings
Item 1. Legal Proceedings.
On February 6, 2025, a purported stockholder of the Company filed a lawsuit against us, certain executive officers, and certain underwriters in the United States District Court for the Southern District of New York (Case No. 1:25-cv-01072). The complaint is a putative class action alleging violations of the Securities Act related to our initial public offering on September 15, 2023. The plaintiff seeks compensatory damages, as well as fees and costs. The complaint claims that our offering documents contained false and misleading statements and omitted material facts about the prospects of navacaprant. We do not believe these allegations have merit and have moved to dismiss. On November 19, 2025, the Court appointed Victor Otcheretko as Lead Plaintiff and on January 14, 2026 Lead Plaintiff Otcheretko filed an amended complaint. On March 11, 2026, defendants filed a motion to dismiss the amended complaint. Lead Plaintiff’s opposition to defendants’ motion to dismiss was filed on April 22, 2026. On May 1, 2026, Lead Plaintiff filed a letter motion requesting leave to file a second amended complaint, which the Court granted on May 5, 2026. Lead Plaintiff filed a second amended complaint on May 5, 2026. Pursuant to the Court’s order, Defendants’ motion(s) to dismiss the second amended complaint is due June 15, 2026, Lead Plaintiff’s opposition(s) to the motion(s) to dismiss are due July 27, 2026, and Defendants’ reply brief(s) are due August 24, 2026. The Court has not yet scheduled a hearing on the anticipated motion(s) to dismiss.
In addition, from time to time, we may in the ordinary course of business become involved in legal proceedings. Regardless of outcome, litigation could have a material adverse effect on our business results of operations or financial condition due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors, and there can be no assurances that favorable outcomes will be obtained.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.